Optimistic Buy Rating for Inventiva Driven by Lanifibranor’s Promising Phase 3 Prospects and Safety Profile

Inventiva (IVA) has received a new Buy rating, initiated by TD Cowen analyst, Ritu Baral.

Ritu Baral’s rating is based on several promising aspects of Inventiva’s pipeline and its lead asset, lanifibranor. The drug, designed to address metabolic conditions like MASH, has shown the potential to significantly reduce insulin resistance, decrease hepatic inflammation, and improve liver fibrosis. Such multi-targeted benefits, coupled with its improved tolerability over existing PPAR agonists and MASH therapies, make it a promising candidate.
Additionally, previous Phase 2 trials have demonstrated statistically significant results in both MASH resolution and fibrosis improvement. The safety profile of lanifibranor is also favorable, especially for diabetic patients, as it avoids the common issue of weight gain associated with other PPAR gamma agonists. These factors collectively support the optimistic outlook for the ongoing Phase 3 trials and potential market approval in the US and EU, justifying the Buy rating.

In another report released on February 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $17.00 price target.